Annexin A1 in blood mononuclear cells from patients with coronary artery disease: Its association with inflammatory status and glucocorticoid sensitivity

Abstract

Annexin A1 (AnxA1) is a key player in resolution of inflammation and a mediator of glucocorticoid actions. In atherosclerotic tissue, increased expression of AnxA1 has been associated with protective plaque-stabilizing effects. Here, we investigated the expression of AnxA1 in peripheral blood mononuclear cells (PBMCs) from patients with coronary artery disease (CAD). Blood was collected from 57 patients with stable CAD (SCAD) and 41 healthy controls. We also included a minor group (n = 10) with acute coronary syndrome (ACS). AnxA1 mRNA was measured in PBMCs. Expression of AnxA1 protein (total and surface-bound) and glucocorticoid receptors (GR) were detected in PBMC subsets by flow cytometry. Also, salivary cortisol, interleukin(IL)-6 and IL-10 in plasma, and LPS-induced cytokine secretion from PBMCs, with or without dexamethasone, were assessed. AnxA1 mRNA was found to be slightly increased in PBMCs from SCAD patients compared with controls. However, protein expression of AnxA1 or GRs in PBMC subsets did not differ between SCAD patients and controls, despite SCAD patients showing a more proinflammatory cytokine profile ex vivo. Only surface expression of AnxA1 on monocytes correlated with dexamethasone-mediated suppression of cytokines. In ACS patients, a marked activation of AnxA1 was seen involving both gene expression and translocation of protein to cell surface probably reflecting a rapid glucocorticoid action modulating the acute inflammatory response in ACS. To conclude, surface expression of AnxA1 on monocytes may reflect the degree of glucocorticoid sensitivity. Speculatively, “normal” surface expression of AnxA1 indicates that anti-inflammatory capacity is impaired in SCAD patients.

Annexin‐1 as a salivary biomarker for gingivitis during pregnancy

“…The association between estrogens and ANXA1 has been previously documented in vitro, and it is well established that hormonal changes influence the composition of saliva, including changes in the protein profiles or the levels of ROS in pregnant women . It may also be stated that ANXA1 is increased in the plasma of women with preeclampsia, and that periodontitis is also associated with preeclampsia and reversed pregnancy outcomes . Collectively, these earlier studies are supported by the present findings demonstrating that ANXA1 levels are increased in the course of gingival inflammation during pregnancy.…”

Differential Effects of Statins on Annexin A1 Serum Level in Patients With Acute Coronary Syndrome: A Pleiotropic Update

“…A previous study exhibited that there was an increased AnxA1 expression in patients with ACS in response to glucocorticoid mediated acute inflammation. (17) In contrast to our study, a study on patients with CHD to evaluate the expression of AnxA1, showed that despite the anti-inflammatory effect of statins there was no change in the expression of glucocorticoids or AnxA1 (18) .…”

Annexin-A1: Therapeutic Potential in Microvascular Disease

“…The observed protective effects of Ac2-50 (a synthetic peptide of the last 28 amino acid of the N-terminal fragment of ANXA1) were lost in FRP2/3 −/− mice suggesting that activation by Ac2-50 of the ALX/FPR2 confers tissue protection (54). In patients with stable coronary artery disease, Bergström et al describe that ANXA1 located on the surface of peripheral monocytes serves as a marker of glucocorticoid sensitivity, thereby reflecting the anti-inflammatory capacity of these cells (55).…”